Ascentage Pharma Group International (AAPG) Common Equity: 2022-2024

Historic Common Equity for Ascentage Pharma Group International (AAPG) over the last 3 years, with Dec 2024 value amounting to $37.6 million.

  • Ascentage Pharma Group International's Common Equity rose 282.88% to $37.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $37.6 million, marking a year-over-year increase of 282.88%. This contributed to the annual value of $37.6 million for FY2024, which is 275.80% up from last year.
  • According to the latest figures from FY2024, Ascentage Pharma Group International's Common Equity is $37.6 million, which was up 275.80% from $10.0 million recorded in FY2023.
  • In the past 5 years, Ascentage Pharma Group International's Common Equity ranged from a high of $60.9 million in FY2022 and a low of $10.0 million during FY2023.
  • Moreover, its 3-year median value for Common Equity was $37.6 million (2024), whereas its average is $36.1 million.
  • Its Common Equity has fluctuated over the past 5 years, first plummeted by 83.58% in 2023, then spiked by 275.80% in 2024.
  • Over the past 3 years, Ascentage Pharma Group International's Common Equity (Yearly) stood at $60.9 million in 2022, then crashed by 83.58% to $10.0 million in 2023, then soared by 275.80% to $37.6 million in 2024.